Answers are grounded in this paper and cite their sources.
Retrospective cohort study shows bridging therapy improves Uveitic Macular Edema outcomes in patients receiving adalimumab, indicating potential benefits.
PURPOSE: Noninfectious uveitic macular edema (UME) is a major cause of visual impairment and remains challenging in refractory cases. Although adalimumab (ADA) is an effective biologic therapy, its delayed onset may limit early disease control, suggesting a potential role for bridging strategies such as local corticosteroid injection. This study compared ADA monotherapy with ADA combined with sub-Tenon's triamcinolone acetonide (STTA) bridging therapy in refractory noninfectious UME. METHODS: In this retrospective longitudinal cohort study, 30 patients (44 eyes) with refractory noninfectious UME treated with ADA (2015-2025) were included. Patients received either ADA monotherapy or ADA with STTA bridging therapy. Outcomes included time to improvement (≥ 20% reduction in central subfield thickness (CST) with reduced cystoid spaces), relapse after resolution, longitudinal CST changes, best-corrected visual acuity (BCVA, LogMAR), and intraocular pressure (IOP). Time-to-event analyses were performed using Cox regression, and Longitudinal data using generalized estimating equation models adjusted for baseline covariates. RESULTS: Bridging therapy was associated with a shorter time to improvement (log-rank p = 0.008; HR 2.850, 95% CI 1.402-5.794; p = 0.004). Adjusted analyses showed greater visual improvement in the bridging group at 12 months (difference 0.307 LogMAR; p < 0.001) and at 15, 24, and 36 months (p < 0.05). Greater CST reductions were observed at 3, 18, 21, and 36 months (p < 0.05). Relapse risk did not differ significantly (HR 0.711, 95% CI 0.155-3.272; p = 0.662). IOP changes were generally comparable. CONCLUSION: ADA combined with STTA bridging therapy was associated with earlier anatomical improvement and additional visual benefits compared with ADA monotherapy, without increased relapse risk.
No takes yet. Share an insight, caveat, or question.
Zou et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: